ArticleFrontiers in surgery2026
The management of solitary fibrous tumor: a single center's experience.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm, with about 30% occurring in the intra-thoracic area. This study describes the clinical characteristics and management strategies for SFT in a single center. Methods: A retrospective review was conducted on patients with pleural SFT who underwent surgery at our institution from January 2005 to August 2023. Data included demographics, tumor features, surgical details, pathology, and follow-up outcomes. Results: Seventeen patients underwent 19 surgeries. The median age was 57 years, and 41% of patients were male. Right-sided tumors accounted for 63% of cases, and 26% of tumors exceeded 10 cm. VATS was used in 68% of procedures. Blood loss varied widely from 50 to 8,600 mL, with a median hospital stay of 6 days. Risk classification included 9 low-risk, 7 intermediate-risk, and 3 high-risk surgical cases. Survival status was available for 13 patients; 12 were alive, and 1 had died from unrelated lung cancer. Conclusion: This single-center experience suggests that complete resection remains central to the management of pleural SFT, and VATS may be feasible in selected cases. Preoperative planning may be useful for large or hypervascular tumors, and long-term follow-up should be considered because recurrence with pathological progression may occur. These findings should be interpreted cautiously given the small sample size and retrospective design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.